Novel genetic associations with interferon in systemic lupus erythematosus identified by replication and fine-mapping of trait-stratified genome-wide screen.


Journal

Cytokine
ISSN: 1096-0023
Titre abrégé: Cytokine
Pays: England
ID NLM: 9005353

Informations de publication

Date de publication:
08 2020
Historique:
received: 11 10 2018
revised: 20 12 2018
accepted: 24 12 2018
pubmed: 28 1 2019
medline: 22 9 2021
entrez: 28 1 2019
Statut: ppublish

Résumé

High serum interferon alpha (IFN-α) is an important heritable phenotype in systemic lupus erythematosus (SLE) which is involved in primary disease pathogenesis. High vs. low levels of IFN-α are associated with disease severity and account for some of the biological heterogeneity between SLE patients. The aim of the study was to replicate and fine-map previously detected genetic associations with serum IFN-α in SLE. We previously undertook a case-case genome-wide association study of SLE patients stratified by ancestry and extremes of phenotype in serum IFN-α. Single nucleotide polymorphisms (SNPs) in seven loci identified in this screen were selected for follow up in a large independent cohort of 1370 SLE patients (703 European-ancestry, 432 African ancestry, and 235 Amerindian ancestry). Each ancestral background was analyzed separately, and ancestry-informative markers were used to control for ancestry and admixture. We find a rare haplotype spanning the promoter region of EFNA5 that is strongly associated with serum IFN-α in both African-American and European-American SLE patients (OR = 3.0, p = 3.7 × 10 This study demonstrates the power of molecular sub-phenotypes to reveal genetic factors involved in complex autoimmune disease. The distinct associations observed in different ancestral backgrounds emphasize the heterogeneity of molecular pathogenesis in SLE.

Sections du résumé

BACKGROUND/PURPOSE
High serum interferon alpha (IFN-α) is an important heritable phenotype in systemic lupus erythematosus (SLE) which is involved in primary disease pathogenesis. High vs. low levels of IFN-α are associated with disease severity and account for some of the biological heterogeneity between SLE patients. The aim of the study was to replicate and fine-map previously detected genetic associations with serum IFN-α in SLE.
METHODS
We previously undertook a case-case genome-wide association study of SLE patients stratified by ancestry and extremes of phenotype in serum IFN-α. Single nucleotide polymorphisms (SNPs) in seven loci identified in this screen were selected for follow up in a large independent cohort of 1370 SLE patients (703 European-ancestry, 432 African ancestry, and 235 Amerindian ancestry). Each ancestral background was analyzed separately, and ancestry-informative markers were used to control for ancestry and admixture.
RESULTS
We find a rare haplotype spanning the promoter region of EFNA5 that is strongly associated with serum IFN-α in both African-American and European-American SLE patients (OR = 3.0, p = 3.7 × 10
CONCLUSION
This study demonstrates the power of molecular sub-phenotypes to reveal genetic factors involved in complex autoimmune disease. The distinct associations observed in different ancestral backgrounds emphasize the heterogeneity of molecular pathogenesis in SLE.

Identifiants

pubmed: 30685201
pii: S1043-4666(19)30002-X
doi: 10.1016/j.cyto.2018.12.014
pmc: PMC7723062
mid: NIHMS1518392
pii:
doi:

Substances chimiques

Ephrin-A5 0
Interferon-alpha 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

154631

Subventions

Organisme : NIAMS NIH HHS
ID : R01 AR057781
Pays : United States
Organisme : NIGMS NIH HHS
ID : U54 GM104938
Pays : United States
Organisme : NIAMS NIH HHS
ID : P30 AR053483
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI144292
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR065964
Pays : United States
Organisme : NIAMS NIH HHS
ID : P30 AR073750
Pays : United States
Organisme : NIAID NIH HHS
ID : L30 AI071651
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR060861
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI082714
Pays : United States
Organisme : NIGMS NIH HHS
ID : P30 GM103510
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Références

J Clin Invest. 2015 Jun;125(6):2220-7
pubmed: 25961450
Genes Immun. 2015 Jan-Feb;16(1):15-23
pubmed: 25338677
Arthritis Rheum. 2011 Apr;63(4):1044-53
pubmed: 21162028
J Cell Sci. 2002 Mar 1;115(Pt 5):1059-72
pubmed: 11870224
Ann Rheum Dis. 2012 Mar;71(3):463-8
pubmed: 22088620
Nat Rev Rheumatol. 2018 Mar 21;14(4):214-228
pubmed: 29559718
Nat Commun. 2017 Jul 17;8:16021
pubmed: 28714469
J Immunol. 2014 Jun 15;192(12):5459-68
pubmed: 24907379
Transl Res. 2010 Mar;155(3):109-17
pubmed: 20171594
Mol Cell Biol. 2003 Jul;23(13):4532-41
pubmed: 12808095
J Immunol. 2011 Aug 1;187(3):1298-303
pubmed: 21705624
Arthritis Rheum. 2005 May;52(5):1491-503
pubmed: 15880830
Bioinformatics. 2005 Jan 15;21(2):263-5
pubmed: 15297300
Annu Rev Immunol. 2014;32:83-119
pubmed: 24364806
Arthritis Rheum. 2004 Dec;50(12):3958-67
pubmed: 15593221
Science. 2007 Aug 31;317(5842):1217-20
pubmed: 17761881
PLoS One. 2013 Jun 24;8(6):e67003
pubmed: 23826184
Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W249-52
pubmed: 15215389
Epigenetics Chromatin. 2015 Nov 24;8:49
pubmed: 26609326
IUBMB Life. 2010 Aug;62(8):597-606
pubmed: 20665622
Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2610-5
pubmed: 12604793
Arthritis Rheum. 2010 Feb;62(2):553-61
pubmed: 20112359
Cell Res. 2014 Jun;24(6):727-41
pubmed: 24732009
Genes Immun. 2007 Sep;8(6):492-502
pubmed: 17581626
J Autoimmun. 2015 Nov;64:125-36
pubmed: 26324017
N Engl J Med. 1979 Jul 5;301(1):5-8
pubmed: 449915
J Immunol. 2009 Jan 1;182(1):34-8
pubmed: 19109131
Cancer Discov. 2011 Sep;1(4):326-37
pubmed: 22586611
Nat Genet. 2008 Feb;40(2):204-10
pubmed: 18204446
Arthritis Rheum. 2008 Jul;58(7):2113-9
pubmed: 18576315
Arthritis Res Ther. 2010;12(4):R151
pubmed: 20659327
J Biomed Biotechnol. 2010;2010:
pubmed: 20706608
Clin Rheumatol. 2005 Apr;24(2):178-81
pubmed: 15565395
Arthritis Rheumatol. 2016 Apr;68(4):932-43
pubmed: 26606652
Ann Rheum Dis. 2011 Oct;70(10):1752-7
pubmed: 21719445
J Interferon Cytokine Res. 2011 Dec;31(12):887-92
pubmed: 21923413
Rev Diabet Stud. 2012 Winter;9(4):188-200
pubmed: 23804260
Arthritis Rheum. 2008 Aug;58(8):2481-7
pubmed: 18668568
Am J Hum Genet. 2007 Sep;81(3):559-75
pubmed: 17701901
J Rheumatol. 2012 Jun;39(6):1238-40
pubmed: 22505704
Int J Clin Rheumtol. 2013 Dec 1;8(6):
pubmed: 24416080
Arthritis Rheum. 2006 Jun;54(6):1906-16
pubmed: 16736505
J Rheumatol. 2012 Jan;39(1):73-8
pubmed: 22045845
Genes Dev. 1999 Dec 1;13(23):3125-35
pubmed: 10601038
Pediatrics. 2011 May;127(5):e1239-46
pubmed: 21502224
Gene. 2018 Aug 20;668:59-72
pubmed: 29775752
Arch Neurol. 2012 Oct;69(10):1303-9
pubmed: 22801747
Blood. 2008 Aug 1;112(3):721-32
pubmed: 18385452

Auteurs

Yogita Ghodke-Puranik (Y)

Colton Center for Autoimmunity, New York University School of Medicine, New York, NY, USA.

Molly Imgruet (M)

Division of Rheumatology, Mayo Clinic, Rochester, MN, USA.

Jessica M Dorschner (JM)

Division of Rheumatology, Mayo Clinic, Rochester, MN, USA.

Prakriti Shrestha (P)

Division of Rheumatology, Mayo Clinic, Rochester, MN, USA.

Kaci McCoy (K)

Division of Rheumatology, Mayo Clinic, Rochester, MN, USA.

Jennifer A Kelly (JA)

Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.

Miranda Marion (M)

Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA.

Joel M Guthridge (JM)

Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.

Carl D Langefeld (CD)

Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA.

John B Harley (JB)

Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine and Cincinnati VA Medical Center, Cincinnati, OH, USA.

Judith A James (JA)

Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.

Kathy L Sivils (KL)

Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.

Timothy B Niewold (TB)

Colton Center for Autoimmunity, New York University School of Medicine, New York, NY, USA. Electronic address: Timothy.Niewold@nyulangone.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH